Journal article icon

Journal article

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.

Abstract:

OBJECTIVE: Budesonide MMX is a novel oral formulation of budesonide that uses Multi-Matrix System (MMX) technology to extend release to the colon. This study compared the efficacy of budesonide MMX with placebo in patients with active, mild-to-moderate ulcerative colitis (UC). DESIGN: Patients were randomised 1:1:1:1 to receive budesonide MMX 9 mg or 6 mg, or Entocort EC 9 mg (budesonide controlled ileal-release capsules; reference arm) or placebo once daily for 8 weeks. The primary endpoint ...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1136/gutjnl-2012-304258

Authors


Expand authors...
Journal:
Gut
Volume:
63
Issue:
3
Pages:
433-441
Publication date:
2014-03-05
DOI:
EISSN:
1468-3288
ISSN:
0017-5749
URN:
uuid:35d084ca-b908-4079-82b4-d0a714640c96
Source identifiers:
388248
Local pid:
pubs:388248

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP